4
Orphan Designations
0 approved, 4 designated
0
FDA Approvals
0
Active Trials
5
Rare Diseases
across 8 areas
0
News (30d)
Quiet
LaNova Medicines Limited is a company with 4 orphan drug designations across 5 rare diseases.
Disease-by-disease pipeline progression from orphan designation through clinical trials to FDA approval.
Source: FDA Orphan Drug Designations, ClinicalTrials.gov, Drugs@FDA
| Disease | Drug(s) | Stage |
|---|---|---|
| carcinoma of liver and intrahepatic biliary tract | an ADC drug against CLDN18.2, containing a recombinant humanized anti-CLDN18.2 IgG1 monoclonal antibody and linker-payload MC-VC-PAB-MMAE | Des.TrialAppr. |
| cholangiocarcinoma | an ADC drug against CLDN18.2, containing a recombinant humanized anti-CLDN18.2 IgG1 monoclonal antibody and linker-payload MC-VC-PAB-MMAE | Des.TrialAppr. |
| gastric cancer | an antibody drug conjugate composed of a humanized monoclonal antibody targeting CLDN18.2 and linker-payload MC-VC-PAB-MMAE | Des.TrialAppr. |
| intrahepatic cholangiocarcinoma | an ADC drug against CLDN18.2, containing a recombinant humanized anti-CLDN18.2 IgG1 monoclonal antibody and linker-payload MC-VC-PAB-MMAE | Des.TrialAppr. |
| malignant pancreatic neoplasm | an IgG1(Immunoglobulin G1) subclass antibody targeting CCR8(C-C Motif Chemokine Receptor 8)an antibody drug conjugate composed of a humanized monoclonal antibody targeting CLDN18.2 and linker-payload MC-VC-PAB-MMAE | Des.TrialAppr. |
0% of portfolio targets high unmet need diseases
40
overlap in 2+ diseases
0/5
candidate diseases
0
avg importance: 0
0
affecting portfolio
0% of portfolio targets high unmet need diseases
40
overlap in 2+ diseases
0/5
candidate diseases
0
avg importance: 0
0
affecting portfolio